Your treatment journey

Overview

This page sets out exactly how treatment runs, so there are no surprises about appointments, prescriptions, costs or monitoring.

Step 1 — Face-to-face assessment

Treatment always begins with an in-person consultation. Nothing is prescribed from an online form. At that appointment we go through:

• your kidney diagnosis, eGFR trend, albuminuria and, where relevant, dialysis modality or transplant history;
• your full medication list, including anything bought over the counter;
• height, weight, BMI and blood pressure;
• your previous attempts at weight loss and what got in the way;
• contraindications to GLP-1 treatment and, for women of childbearing age, contraception;
• your goal — better health, symptom relief, or reaching a transplant listing threshold.

You will leave with a clear answer about suitability, not a maybe.

Step 2 — Consent and prescription

If treatment is appropriate, you sign a written treatment agreement covering how the medicine works, the side effects, the monitoring you are agreeing to, and the circumstances in which treatment would be stopped. Your signed agreement is stored on your record here and you can read it back at any time.

The prescription is then dispensed by the pharmacy — not by this website.

Step 3 — Weekly logging

You are invited to this platform and log your weight once a week. Where creatinine monitoring applies, results are added to your record so weight and kidney function can be read side by side. Missing a weekly weight raises a flag for the clinical team.

Step 4 — Six-weekly clinical review

Every six weeks your record is reviewed: weight trend, tolerance, dose, blood results, and whether other medicines need reducing as weight falls. Dose changes are made here, and each change is recorded with its date.

Step 5 — Longer-term review

• At 26 weeks, a formal outcome review asks whether the treatment is delivering enough benefit to justify continuing.
• Semaglutide (Wegovy) treatment is subject to NICE's two-year maximum, and your record tracks the elapsed time so this is never missed.
• Tirzepatide has no fixed stopping point but requires continuing review to remain appropriate.

Which system does what

• Booking and initial payment — professoralthaf.co.uk
• Medication supply and payment — Healist Pharmacy
• Follow-up appointment payment — Carebit
• Your clinical monitoring record — this platform

No payment is ever taken on this website.

What we expect from you

• Log your weight every week.
• Report side effects early rather than stopping the medicine silently.
• Keep your renal team informed that you are on treatment, and share results both ways.
• Follow your sick-day rules.

When to contact your care team

Contact the clinic promptly if you have any of the following:

• Vomiting or diarrhoea lasting more than 24 hours, or you cannot keep fluids down
• Passing much less urine than usual, or new swelling of the legs or face
• Severe pain in the upper abdomen that spreads to your back, with or without vomiting
• A weight change of more than 2 kg in a week that is not explained by fluid
• A missed weekly weight, a missed dose, or any hospital admission

If you are seriously unwell, contact NHS 111 or your renal unit directly rather than waiting for your next review.

References

• NICE TA875 — Semaglutide for managing overweight and obesity
• NICE TA1026 — Tirzepatide for managing overweight and obesity
• NICE CG189 — Obesity: identification, assessment and management
• NICE NG203 — Chronic kidney disease: assessment and management
• NHS — Chronic kidney disease
• UK Kidney Association clinical practice guidelines

This page is general information, medically reviewed for accuracy.